Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study.
Kidney transplant
Monoclonal antibodies
Prophylaxis
SARS-CoV-2
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
23 May 2024
23 May 2024
Historique:
received:
18
04
2023
accepted:
05
01
2024
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
23
5
2024
Statut:
aheadofprint
Résumé
Immunocompromised patients show an impaired vaccine response and remain at high risk of severe COVID-19, despite vaccination. Neutralizing monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed for prophylaxis and treatment. The combination tixagevimab/cilgavimab (AZD7442) has been authorized for emergency use as pre-exposure prophylaxis for COVID-19, but data on safety and efficacy in kidney transplant recipients during the Omicron period are limited. We conducted a multicenter retrospective cohort study including 253 kidney transplant recipients, of whom 98 were treated with tixagevimab/cilgavimab 150 mg/150 mg and 155 who received only four doses of the BNT162b2 mRNA vaccine. Only 13.3% of patients developed SARS-CoV-2 infection after the administration of tixagevimab/cilgavimab; in comparison, 34.2% of patients had been infected after the fourth dose of vaccine (p = 0.00013). Most infected patients in the AZD7442 group remained asymptomatic (92.3% vs 54.7%), 7.7% had mild symptoms and none had severe disease, need for hospitalization or died, while in the control group, 9.4% of patients had moderate or severe disease (p = 0.04). Using Kaplan-Meier curves we demonstrated that the controls presented early infection compared to the AZD7442 group (p = 0.000014). No changes in eGFR or proteinuria, assessed before and after the administration, were observed. In conclusion, our study showed that tixagevimab/cilgavimab 150/150 mg is effective and safe in preventing infection and severe disease when administered to patients with weak or no response to COVID-19 vaccine.
Sections du résumé
BACKGROUND
BACKGROUND
Immunocompromised patients show an impaired vaccine response and remain at high risk of severe COVID-19, despite vaccination. Neutralizing monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed for prophylaxis and treatment. The combination tixagevimab/cilgavimab (AZD7442) has been authorized for emergency use as pre-exposure prophylaxis for COVID-19, but data on safety and efficacy in kidney transplant recipients during the Omicron period are limited.
METHODS
METHODS
We conducted a multicenter retrospective cohort study including 253 kidney transplant recipients, of whom 98 were treated with tixagevimab/cilgavimab 150 mg/150 mg and 155 who received only four doses of the BNT162b2 mRNA vaccine.
RESULTS
RESULTS
Only 13.3% of patients developed SARS-CoV-2 infection after the administration of tixagevimab/cilgavimab; in comparison, 34.2% of patients had been infected after the fourth dose of vaccine (p = 0.00013). Most infected patients in the AZD7442 group remained asymptomatic (92.3% vs 54.7%), 7.7% had mild symptoms and none had severe disease, need for hospitalization or died, while in the control group, 9.4% of patients had moderate or severe disease (p = 0.04). Using Kaplan-Meier curves we demonstrated that the controls presented early infection compared to the AZD7442 group (p = 0.000014). No changes in eGFR or proteinuria, assessed before and after the administration, were observed.
CONCLUSIONS
CONCLUSIONS
In conclusion, our study showed that tixagevimab/cilgavimab 150/150 mg is effective and safe in preventing infection and severe disease when administered to patients with weak or no response to COVID-19 vaccine.
Identifiants
pubmed: 38780697
doi: 10.1007/s40620-024-01889-9
pii: 10.1007/s40620-024-01889-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Haidar G, Mellors JW (2021) Improving the outcomes of immunocompromised patients with coronavirus disease 2019. Clin Infect Dis 73(6):e1397–e1401
doi: 10.1093/cid/ciab397
pubmed: 33949644
pmcid: 8135839
Bergman P, COVAXID-Collaborator Group et al (2021) Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine 74:103705
doi: 10.1016/j.ebiom.2021.103705
pubmed: 34861491
pmcid: 8629680
Ślizień Z et al (2022) Safety and tolerability of mRNA COVID-19 vaccines in kidney transplant recipients. Transplant Proc 54(4):878–883
doi: 10.1016/j.transproceed.2022.02.025
pubmed: 35961734
pmcid: 8926897
Boyarsky BJ, Werbel WA, Avery RK et al (2021) Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 325(21):2204–2206
doi: 10.1001/jama.2021.7489
pubmed: 33950155
pmcid: 8100911
Rincon-Arevalo H et al (2021) Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol 6(60):eanj1031
doi: 10.1126/sciimmunol.abj1031
Simone S et al (2023) Kinetics of humoral immune response and severity of infection after three doses of SARS-CoV-2 mRNA vaccine in a large cohort of kidney transplant recipients. J Nephrol 36(6):1663–1671
doi: 10.1007/s40620-023-01650-8
pubmed: 37458909
pmcid: 10393874
Tixagevimab and cilgavimab (evusheld) for pre-exposure prophylaxis of COVID-19. JAMA. 2022;327(4):384–385.
Abraham J (2022) Monoclonal antibodies with extended half-life to prevent COVID-19. N Engl J Med 386(23):2236–2238
doi: 10.1056/NEJMe2205563
pubmed: 35675183
pmcid: 9202318
Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, Ambery P, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Near KA, Padilla KW, Psachoulia K, Sharbaugh A, Streicher K, Pangalos MN, Esser MT, PROVENT Study Group (2022) Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of COVID-19. N Engl J Med 386(23):2188–2200
doi: 10.1056/NEJMoa2116620
pubmed: 35443106
Benotmane I et al (2022) Pre-exposure prophylaxis with 300 mg evusheld elicits limited neutralizing activity against the Omicron variant. Kidney Int 102(2):442–444
doi: 10.1016/j.kint.2022.05.008
pubmed: 35618094
pmcid: 9126611
https://www.epicentro.iss.it/coronavirus/sars-cov-2-monitoraggio-varianti-rapporti-periodici . Accessed 29 Apr 2022.
Kim K, Cho K, Song J, Rahmati M, Koyanagi A, Lee SW, Yon DK, Il Shin J, Smith L (2023) The case fatality rate of COVID-19 during the delta and the omicron epidemic phase: a meta-analysis. J Med Virol 95(2):e28522
doi: 10.1002/jmv.28522
pubmed: 36691933
Theodore DA, Branche AR, Zhang L, COVID-19 Prevention Network (CoVPN) et al (2023) Clinical and demographic factors associated with COVID-19, severe COVID-19, and SARS-CoV-2 infection in adults: a secondary cross-protocol analysis of 4 randomized clinical trials. JAMA Netw Open 6(7):e2323349
doi: 10.1001/jamanetworkopen.2023.23349
pubmed: 37440227
pmcid: 10346130
Bahremand T et al (2023) COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada. Lancet Reg Health Am 20:100461
pubmed: 36890850
pmcid: 9987330
Chiang TP et al (2023) Incident COVID-19 and hospitalizations by variant era among vaccinated solid organ transplant recipients. JAMA Netw Open 6(8):e2329736
doi: 10.1001/jamanetworkopen.2023.29736
pubmed: 37594763
pmcid: 10439474
Lauring AS, Influenza and Other Viruses in the Acutely Ill (IVY) Network et al (2022) Clinical severity of, and effectiveness of mRNA vaccines against, COVID-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ 376:e069761
doi: 10.1136/bmj-2021-069761
pubmed: 35264324
Wong G et al (2022) COVID-19 infection with the omicron SARS-CoV-2 variant in a cohort of kidney and kidney pancreas transplant recipients: clinical features, risk factors, and outcomes. Transplantation 106(9):1860–1866
doi: 10.1097/TP.0000000000004203
pubmed: 35675438
Cristelli MP et al (2022) How did the omicron surge affect kidney transplant recipients compared with a cohort from the general population? Transplantation 106(8):e382–e383
doi: 10.1097/TP.0000000000004193
pubmed: 35594475
pmcid: 9311286
Kneidinger N et al (2023) Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study. Infection 51:749–757
doi: 10.1007/s15010-022-01914-8
pubmed: 36083405
Kumar D et al (2022) Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine. Am J Transplant 22(8):2089–2093
doi: 10.1111/ajt.17020
pubmed: 35266606
pmcid: 9111417
Benning L et al (2022) Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients. Am J Transplant 22(7):1873–1883
doi: 10.1111/ajt.17054
pubmed: 35384272
pmcid: 9111366
Fernandes G et al (2022) Monoclonal antibody therapy in kidney transplant recipients with delta and omicron variants of SARS-CoV-2: a single-center case series. Kidney Med 4(6):100470
doi: 10.1016/j.xkme.2022.100470
pubmed: 35493029
pmcid: 9042411
Ducloux D, Courivaud C (2022) REGEN-Cov antibody combination to prevent COVID-19 infection in kidney transplant recipient without detectable antibody response to optimal vaccine scheme. Kidney Int 101(3):645–646
doi: 10.1016/j.kint.2021.12.015
pubmed: 34995651
pmcid: 8724020
Al Jurdi A et al (2022) Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave. Am J Transplant 22(12):3130–3136
doi: 10.1111/ajt.17128
pubmed: 35727916
Flahault A et al (2022) Breakthrough omicron COVID-19 infections in patients receiving the REGEN-Cov antibody combination. Kidney Int 101(4):824–825
doi: 10.1016/j.kint.2022.01.016
pubmed: 35157894
pmcid: 8837470
Benotmane I et al (2022) Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients. Am J Transplant. https://doi.org/10.1111/ajt.17121
doi: 10.1111/ajt.17121
pubmed: 35713984
pmcid: 9800460
Kaminski H et al (2022) COVID-19 morbidity decreases with tixagevimab-cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders. Kidney Int 102(4):936–938
doi: 10.1016/j.kint.2022.07.008
pubmed: 35870641
pmcid: 9297679
Nguyen Y, Flahault A, Chavarot N et al (2022) Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld©) for COVID-19 among 1112 severely immunocompromised patients. Clin Microbiol Infect 28(12):1654.e1-1654.e4. https://doi.org/10.1016/j.cmi.2022.07.015
doi: 10.1016/j.cmi.2022.07.015
pubmed: 35926762
Bertrand D et al (2022) Efficacy of anti-SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients. Kidney Int 102(2):440–442. https://doi.org/10.1016/j.kint.2022.05.007 . (Epub 2022 May 23)
doi: 10.1016/j.kint.2022.05.007
pubmed: 35618097
pmcid: 9125992
Nagarajan R, Krishnamoorthy Y, Rajaa S, Hariharan VS (2022) COVID-19 severity and mortality among chronic liver disease patients: a systematic review and meta-analysis. Prev Chronic Dis 19:210228
doi: 10.5888/pcd19.210228
Moon AM, Webb GJ, Aloman C et al (2020) High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry. J Hepatol 73(3):705–708 (Epub 2020 May 21)
doi: 10.1016/j.jhep.2020.05.013
pubmed: 32446714
pmcid: 7241346
Liu Z, Hu D, Li J, Xia Q, Gong Y, Li Z, Wu Q, Yi M, Huang Y, Wu M, Guo L, Wu X (2021) Prognostic potential of liver enzymes in patients with COVID-19 at the Leishenshan Hospital in Wuhan. Front Cell Infect Microbiol 11:636999
doi: 10.3389/fcimb.2021.636999
pubmed: 34869048
pmcid: 8635154
Roel E, Pistillo A, Recalde M et al (2021) Characteristics and outcomes of over 300,000 patients with COVID-19 and history of cancer in the United States and Spain. Cancer Epidemiol Biomarkers Prev 30(10):1884–1894 (Epub 2021 Jul 16)
doi: 10.1158/1055-9965.EPI-21-0266
pubmed: 34272262
pmcid: 8974356
Tian J, Yuan X, Xiao J et al (2020) Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol 21(7):893–903 (Epub 2020 May 29)
doi: 10.1016/S1470-2045(20)30309-0
pubmed: 32479790
pmcid: 7259911
Sengar M, Chinnaswamy G, Ranganathan P et al (2022) Outcomes of COVID-19 and risk factors in patients with cancer. Nat Cancer 3:547–551
doi: 10.1038/s43018-022-00363-4
pubmed: 35379984
Várnai C, Palles C, Arnold R et al (2022) Mortality among adults with cancer undergoing chemotherapy or immunotherapy and infected with COVID-19. JAMA Netw Open 5(2):e220130
doi: 10.1001/jamanetworkopen.2022.0130
pubmed: 35188551
pmcid: 8861846
Bruel T, Hadjadj J, Maes P et al (2022) Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med 28:1297–1302. https://doi.org/10.1038/s41591-022-01792-5
doi: 10.1038/s41591-022-01792-5
pubmed: 35322239
Benotmane I et al (2022) A rapid decline in the anti-receptor-binding domain of the SARS-CoV-2 spike protein IgG titer in kidney transplant recipients after tixagevimab-cilgavimab administration. Kidney Int 102(5):1188–1190. https://doi.org/10.1016/j.kint.2022.07.022 . (Epub 2022 Aug 13)
doi: 10.1016/j.kint.2022.07.022
pubmed: 35973595
pmcid: 9375643
Gilbert PB et al (2022) A covid-19 milestone attained—a correlate of protection for vaccines. N Engl J Med 387(24):2203–2206
doi: 10.1056/NEJMp2211314
pubmed: 36507702
Follmann D et al (2023) Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration. Nat Commun 14(1):3605
doi: 10.1038/s41467-023-39292-w
pubmed: 37330602
pmcid: 10276829
Akinosoglou K, Rigopoulos EA et al (2022) Tixagevimab/cilgavimab in SARS-CoV-2 prophylaxis and therapy: a comprehensive review of clinical experience. Viruses 15(1):118
doi: 10.3390/v15010118
pubmed: 36680160
pmcid: 9866621
Keam SJ (2022) Tixagevimab + cilgavimab: first approval. Drugs 82(9):1001–1010
doi: 10.1007/s40265-022-01731-1
pubmed: 35727563
pmcid: 9211051
Karaba AH, Kim JD, Chiang TP, et al. Omicron BA.1 and BA.2 Neutralizing activity following pre-exposure prophylaxis with tixagevimab plus cilgavimab in vaccinated solid organ transplant recipients. medRxiv [Preprint]. 2022:2022.05.24.22275467 (Update in: Clin Exp Rheumatol. 2023 Feb 23).
VanBlargan LA et al (2022) An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med 28(3):490–495. https://doi.org/10.1038/s41591-021-01678-y . (Epub 2022 Jan 19)
doi: 10.1038/s41591-021-01678-y
pubmed: 35046573
pmcid: 8767531
Tao K, Tzou PL, Kosakovsky Pond SL, Ioannidis JPA, Shafer RW (2022) Susceptibility of SARS-CoV-2 omicron variants to therapeutic monoclonal antibodies: systematic review and meta-analysis. Microbiol Spectr. 10(4):e0092622. https://doi.org/10.1128/spectrum.00926-22 . (Epub 2022 Jun 14)
doi: 10.1128/spectrum.00926-22
pubmed: 35700134
Boschi C, Colson P, Bancod A, Moal V, La Scola B (2022) Omicron variant escapes therapeutic monoclonal antibodies (mabs) including recently released Evusheld
doi: 10.1093/cid/ciac143
pubmed: 35171987
pmcid: 9402686